Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tremelimumab plus durvalumab prior to chemoradiotherapy in unresectable, locally advanced non-small cell lung cancer: the Induction trial.
Smeenk MM, van Diessen JNA, Boellaard TN, Hartemink KJ, de Vries JF, van der Noort V, Badrising SK, Owers EC, Monkhorst K, van den Heuvel MM, Theelen WSME. Smeenk MM, et al. Among authors: owers ec. Clin Cancer Res. 2025 Jan 17. doi: 10.1158/1078-0432.CCR-24-3476. Online ahead of print. Clin Cancer Res. 2025. PMID: 39821070
Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.
Verschoor YL, van de Haar J, van den Berg JG, van Sandick JW, Kodach LL, van Dieren JM, Balduzzi S, Grootscholten C, IJsselsteijn ME, Veenhof AAFA, Hartemink KJ, Vollebergh MA, Jurdi A, Sharma S, Spickard E, Owers EC, Bartels-Rutten A, den Hartog P, de Miranda NFCC, van Leerdam ME, Haanen JBAG, Schumacher TN, Voest EE, Chalabi M. Verschoor YL, et al. Among authors: owers ec. Nat Med. 2024 May;30(5):1499. doi: 10.1038/s41591-024-02898-8. Nat Med. 2024. PMID: 38448792 Free PMC article. No abstract available.
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.
Verschoor YL, van de Haar J, van den Berg JG, van Sandick JW, Kodach LL, van Dieren JM, Balduzzi S, Grootscholten C, IJsselsteijn ME, Veenhof AAFA, Hartemink KJ, Vollebergh MA, Jurdi A, Sharma S, Spickard E, Owers EC, Bartels-Rutten A, den Hartog P, de Miranda NFCC, van Leerdam ME, Haanen JBAG, Schumacher TN, Voest EE, Chalabi M. Verschoor YL, et al. Among authors: owers ec. Nat Med. 2024 Feb;30(2):519-530. doi: 10.1038/s41591-023-02758-x. Epub 2024 Jan 8. Nat Med. 2024. PMID: 38191613 Free PMC article. Clinical Trial.
Hybrid training in nuclear medicine: where are we going to?
Stokkel MPM, Owers EC. Stokkel MPM, et al. Among authors: owers ec. Eur J Nucl Med Mol Imaging. 2023 Jul;50(8):2231-2235. doi: 10.1007/s00259-023-06223-2. Eur J Nucl Med Mol Imaging. 2023. PMID: 37052628 No abstract available.